Foster®

Brand Chiesi Pharmaceutical SpA

In stock 1004 Items

Available since: 2019-09-19

All payments are SSL encrypted
Full Refund if you haven't received your order
International shipping to the USA, UK and Europe

Clinical Pharmacology

Foster has an anti-inflammatory effect, reduces the severity of symptoms of bronchial asthma and reduces the frequency of exacerbations of the disease, while having a lower incidence of side effects than systemic GCS.

Indications

Basic therapy of bronchial asthma, providing for the appointment of a combination therapy (inhaled glucocorticosteroid and β 2 long-acting adrenergic mimic):
Patients whose symptoms are ill-controlled by inhaled glucocorticosteroids and β 2 short-acting adrenergic mimetics.
Patients receiving effective maintenance doses of inhaled glucocorticosteroids and long-acting β 2 adrenergic mimetics.

Composition

1 dose contains beclomethasone dipropionate 100 μg, formoterol fumarate 6 μg.

No customer reviews for the moment.

Write your review

Dosage and Administration

Selection of the dose of drugs that are part of Foster, occurs individually and depending on the severity of the disease. For adults and adolescents over 12 years old: 1-2 inhalations twice a day. Patients should be under the constant supervision of a physician for an adequate selection of the Foster dose. The dose should be reduced to the lowest, against which the optimal control of the symptoms of bronchial asthma is maintained. When achieving complete control over the symptoms of bronchial asthma on the background of the minimum recommended dose of the drug, in the next step, you can try the appointment of monotherapy with inhaled glucocorticosteroids.
There is no need for a special selection of the dose of the drug for elderly patients.

Adverse reactions

Among the most frequent side effects associated with formoterol, described are typical for beta2-adrenergic mimics, such as: hypokalemia, headache, tremor, palpitations, cough, muscle cramps, lengthening of the QTc interval. Side effects characteristic of beclomethasone dipropionate: candidiasis of the mucous membrane of the mouth and pharynx, irritation in the throat.
Like other inhalants, Foster can cause paradoxical bronchospasm.
Other side effects characteristic of formoterol thrombocytopenia, angioneurotic edema, hyperglycemia, increased blood levels of insulin, free fatty acids, glycerol and ketone derivatives, sleep disorders, hallucination, fatigue, restlessness, changes in taste (dysgeusia), tachycardia, tachyarrhythmia, ventricular premature beats, angina (ischemic heart disease), atrial fibrillation, arterial hypertension, arterial hypotension, exacerbation of bronchial asthma, shortness of breath, nausea, itching, skin rash, urticaria, hyperhidrosis, myalgia, nephritis, peripheral edema.

Contraindications

Hypersensitivity to Foster components, children under 12 years old.
Carefully:
Pregnancy, lactation period, pulmonary tuberculosis, fungal, viral or bacterial respiratory infections, thyrotoxicosis, artificial hypothyroidism, artificial hypothyroidism; diseases (acute myocardial infarction, ischemic heart disease, tachyarrhythmia, decompensated chronic heart failure, prolonged nd Q-Tc interval (reception formoterol can cause elongation QTs- interval)).

Drug interactions

Β-adrenergic receptor blockers may weaken the action of formoterol. Foster should not be administered simultaneously with b-adrenoblockers (including eye drops), except in forced cases.

Pregnancy and Lactation

There is no clinical data on the use of Foster during pregnancy. No embryotoxic or teratogenic effects have been identified in animal studies.

In pregnancy, Foster should be used only in cases where the benefits of the drug outweigh the potential risk to the fetus. It is recommended to prescribe a minimum dose that provides effective control of symptoms of bronchial asthma.

There is no data on the penetration of Foster into the breast milk of women. Foster can be prescribed to lactating women only in cases where the expected therapeutic effect for the mother outweighs the potential risk to the baby.

Special instructions

It is recommended to instruct the patient about the need to rinse the mouth with water after inhalation of maintenance doses in order to prevent the risk of developing candidiasis of the mucous membrane of the oral cavity and pharynx.

The balloon is under pressure: do not expose to heat, do not pierce, do not throw into the fire, even empty. Use within 3 months from the start of use.

Overdosage

Symptoms: overdose occurs typical of beta₂adrenomimetic symptoms of formoterol, such as nausea, vomiting, headache, tremor, drowsiness, heart palpitations, tachycardia, ventricular arrhythmia, prolongation of the QTc interval, metabolic acidosis, hypokalemia, hyperglycemia.

Treatment: symptomatic treatment. In severe cases, hospitalization. The use of cardioselective beta-blockers may be considered with caution, since the use of these agents may cause bronchospasm. It is necessary to monitor the level of potassium in the blood plasma.

Inhalation of higher doses of beclomethasone dipropionate may cause a temporary inhibition of the function of the adrenal cortex. Usually this does not require any emergency measures, since in most cases the normal function of the adrenal glands is restored within a few days. It is recommended to monitor the level of cortisol in the blood plasma.

In case of chronic intake of excessive doses of beclomethasone dipropionate, its systemic effect may manifest itself: a significant inhibition of the adrenal cortex can occur up to the adrenal crisis. Acute adrenal crisis is manifested by hypoglycemia, accompanied by confusion and / or convulsions. The situations that can serve as trigger factors for acute adrenal crisis include trauma, surgery, infection, or a rapid reduction in the dose of beclomethasone, which is part of Foster. In chronic overdose, it is recommended to monitor the reserve function of the adrenal cortex.